The Delaware Supreme Court affirmed Friday a trial court’s decision in favor of Teva Pharmaceutical Industries Ltd.'s US unit ...

UBS analyst Ashwani Verma increased the price target for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to $30 from the previous $28 while keeping a Buy rating on the shares. Verma highlighted Teva as ...

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on TEVA stock, giving a Buy rating on January 21.Invest ...

Diversify Advisory Services LLC raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 2.5% during the fourth quarter, according to its most recent ...

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

Teva Pharmaceutical Industries (NYSE:TEVA), a global leader in generic and specialty medicines with a market capitalization of $24.6 billion, has been navigating a complex landscape of legal ...

Teva Pharmaceutical Industries sues CMS over Medicare drug pricing negotiations policy, claiming agency has unchecked ...

Teva Pharmaceuticals challenges the Inflation Reduction Act, arguing CMS's drug pricing policies harm generics, biosimilars, ...

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eight brokerages that are covering the stock, ...

The Delaware Supreme Court appeared skeptical Wednesday of arguments that a trial judge misinterpreted contract language ...